EUVIMEDEUVIMED entdecken
Open Access

Impact of graft‐versus‐host disease prophylaxis strategies on GvHD ‐free/relapse‐free survival in young adults undergoing unrelated donor allogeneic haematopoietic cell transplantation: A propensity score‐matched analysis

Nihar Desai iD, Sergio Rodriguez Rodriguez, Eshrak Al-Shaibani iD, Tommy Alfaro Moya iD, Igor Novitzky-Basso, Arjun Datt Law

British Journal of Haematology · 2026

DOI: 10.1111/bjh.70269 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, 2026. Verfasst von Nihar Desai und 5 weiteren Autor:innen. Beteiligte Einrichtung: Hans Messner Allogeneic Blood and Marrow Transplant Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, O…. Hauptthemen laut MEDLINE: Graft vs Host Disease, Hematopoietic Stem Cell Transplantation. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Office of Naval Research, NCI NIH HHS, HRSA HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Young adults (YAs) undergoing allogeneic haematopoietic stem cell transplantation (HSCT) represent a unique population with distinct medical and psychosocial needs. Optimizing graft‐versus‐host disease (GvHD) prophylaxis in this population remains critical to improving outcomes. We performed a retrospective analysis of YAs undergoing unrelated donor HSCT using a contemporary Center for International Blood and Marrow Transplant Research (CIBMTR) dataset. GvHD‐free, relapse‐free survival (GRFS) at 24 months was evaluated across three GvHD prophylaxis strategies: Group A (post‐transplant cyclophosphamide [PTCy] + calcineurin inhibitor [CNI] + mycophenolate mofetil [MMF]), Group B (CNI + methotrexate [MTX]/MMF), and Group C (CNI + MTX/MMF + anti‐thymocyte globulin [ATG]). A propensity score‐matched (PSM) analysis was conducted to adjust for baseline differences. A total of 1387 YA patients were included. In the total cohort, 24‐month GRFS was 58.9% (confidence intervals [95% CI], 53–64) in Group A, 32.2% (95% CI, 29–36) in Group B and 44.2% (95% CI, 39–49) in Group C ( p < 0.001). On multivariable analysis (MVA), both Group A (hazard ratio [HR] = 0.44; 95% CI, 0.35–0.54) and Group C (HR = 0.79; 95% CI, 0.70–0.90) showed improved GRFS compared to Group B. In the propensity score‐matched cohort, GRFS at 24 months remained higher in the PTCy group (58.2%, 95% CI, 52–64) versus the CNI‐MTX/MMF ± ATG group (32.9%, 95% CI, 27–39; p < 0.001), with PTCy independently associated with improved GRFS (HR = 0.48; 95% CI, 0.40–0.60; p < 0.001). PTCy‐based prophylaxis also reduced non‐relapse mortality (NRM), with no significant differences in relapse or overall survival (OS) between groups. In this large, retrospective analysis, PTCy was associated with significantly improved GRFS and reduced NRM in YAs undergoing unrelated donor HSCT. These findings support the use of PTCy‐based regimens in this population and warrant prospective evaluation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Graft vs Host DiseaseHematopoietic Stem Cell TransplantationHumansMaleFemaleAdultUnrelated DonorsRetrospective StudiesPropensity ScoreYoung AdultAdolescentMethotrexateDisease-Free SurvivalAntilymphocyte SerumTransplantation, HomologousImmunosuppressive AgentsCyclophosphamideTransplantation ConditioningCalcineurin InhibitorsMycophenolic Acid

Stichwörter der Autor:innen

GvHD prophylaxisPTCyallogeneic transplantyoung adults

Substanzen

MethotrexateAntilymphocyte SerumImmunosuppressive AgentsCyclophosphamideCalcineurin InhibitorsMycophenolic Acid

Autor:innen und Institutionen

  • Hans Messner Allogeneic Blood and Marrow Transplant Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • Department of Medicine, University of Toronto, Toronto, Ontario, Canada.

ORCID-Profile: Nihar Desai, Eshrak Al-Shaibani, Tommy Alfaro Moya

Förderung

  • Office of Naval Research
  • NCI NIH HHS
  • HRSA HHS
  • Medical College of Wisconsin
  • National Marrow Donor Program
  • National Institute of Allergy and Infectious Diseases
  • NHLBI NIH HHS
  • National Cancer Institute

Zitieren

APA

Desai, N., Rodriguez, S. R., Al-Shaibani, E., Moya, T. A., Novitzky-Basso, I., & Law, A. D. (2026). Impact of graft‐versus‐host disease prophylaxis strategies on GvHD ‐free/relapse‐free survival in young adults undergoing unrelated donor allogeneic haematopoietic cell transplantation: A propensity score‐matched analysis. British Journal of Haematology. https://doi.org/10.1111/bjh.70269

Vancouver

Desai N, Rodriguez SR, Al-Shaibani E, Moya TA, Novitzky-Basso I, Law AD. Impact of graft‐versus‐host disease prophylaxis strategies on GvHD ‐free/relapse‐free survival in young adults undergoing unrelated donor allogeneic haematopoietic cell transplantation: A propensity score‐matched analysis. British Journal of Haematology. 2026. doi:10.1111/bjh.70269

BibTeX
@article{Desai2026,
  author = {Desai, Nihar and Rodriguez, Sergio Rodriguez and Al-Shaibani, Eshrak and Moya, Tommy Alfaro and Novitzky-Basso, Igor and Law, Arjun Datt},
  title = {Impact of graft‐versus‐host disease prophylaxis strategies on GvHD ‐free/relapse‐free survival in young adults undergoing unrelated donor allogeneic haematopoietic cell transplantation: A propensity score‐matched analysis},
  journal = {British Journal of Haematology},
  year = {2026},
  doi = {10.1111/bjh.70269}
}
Kostenlos starten →